Aptevo Therapeutics Inc. revenue

Aptevo Therapeutics Inc.'s revenue was $3.1m in fiscal 2022, down 74.7% on the year before. Since fiscal 2015 ($33.6m) it has grown at a compound -28.8% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Aptevo Therapeutics Inc.: revenue history, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022
Revenue	34	10	15	23	32	4	12	3
Growth on the year before	—	−70.3%	+46.8%	+57.4%	+40.6%	−86.7%	+185.3%	−74.7%
Gross profit	—	—	—	12	12	—	—	—
Gross margin	—	—	—	51.4%	38.5%	—	—	—

US$ thousands unless shown otherwise. Fiscal quarters.

Aptevo Therapeutics Inc.: revenue history, quarterly
Quarter	2021 Q1Mar 2021	2021 Q2Jun 2021	2021 Q3Sept 2021	2021 Q4Dec 2021	2022 Q1Mar 2022	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022
Revenue	2,421	3,110	3,096	3,665	3,114	0	0	0
Growth on the same quarter a year before	—	—	—	—	+28.6%	−100.0%	−100.0%	−100.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Aptevo Therapeutics Inc.	$3.1m	-74.7%	-48.7%
Upstream Bio, Inc.	$3.2m	16.0%	—
Xenetic Biosciences, Inc.	$3.3m	33.3%	14.7%
Aligos Therapeutics, Inc.	$3.7m	19.4%	-5.5%
Dyadic International Inc	$3.8m	-8.0%	3.4%
DBV Technologies S.a.	$3.8m	-31.6%	-11.6%

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Aptevo Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aptevo Therapeutics Inc.